Clinical Trial Update: Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control [Phase 3]

View source ↗

Summary

Phase 3 trial assessing mepolizumab as an adjunctive therapy in severe eosinophilic asthma; results completed with posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Mepolizumab (mepolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2017-05-04